Cisplatin News and Research

RSS

Osimertinib plus chemotherapy shows significant PFS benefit in advanced EGFR-mutated NSCLC

Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

Study identifies potential target for reversing drug resistance in ovarian cancer

For the 314,000 people diagnosed with ovarian cancer each year, hope often comes in the form of platinum-based drugs such as cisplatin.

5 Sep 2023

Silencing two genes can make cancer cells receptive to chemotherapy

Scientists from Queen Mary University of London have discovered two new genes that cause head and neck cancer patients to be resistant to chemotherapy, and that silencing either gene can make cancer cells previously unresponsive to chemotherapy subsequently respond to it.

4 Sep 2023

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research.

1 Aug 2023

Researchers investigate the efficacy of a novel intra-tumoral drug delivery carrier in treating oral squamous cell carcinoma

Researchers investigated the efficacy of a novel intra-tumoral drug delivery carrier in treating oral squamous cell carcinoma.

31 Jul 2023

Researchers develop first therapy of its kind to treat cisplatin-resistant prostate cancer

Prostate cancer is a leading cause of death among American men, and it's resistant to one of the most powerful chemotherapy medications -; cisplatin.

12 Jul 2023

Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations

Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations.

5 Jun 2023

Patient-derived head and neck cancer organoids could aid the discovery of novel therapies

Researchers from the Organoid group (Hubrecht Institute) and UMC Utrecht have developed a biobank with organoids derived from patients with head and neck cancer (HNC).

12 May 2023

Using a gene signature to predict cancer patient's response to chemotherapy agent cisplatin

Researchers at Cleveland Clinic have taken an important step in predicting which treatment will work for individual cancer patients.

21 Apr 2023

Bonn researchers elucidate a mechanism underlying cisplatin resistance in testicular cancer

Cisplatin is used successfully in the chemotherapy of testicular cancer. However, patients who develop resistance to the cytostatic drug urgently need alternative therapy options.

11 Apr 2023

New anticancer agent activated by ultrasound waves does not have strong side effects

Chemotherapy treatments produce strong side effects. A new agent that accumulates in the tumor tissue and is activated thereby ultrasound waves does not have this problem.

5 Apr 2023

3D cell culture system tests how inhibiting fibroblast activities can help treat lung cancer

Fibroblasts build and maintain the extracellular matrix, or physical scaffolding for cells, in the connective tissues within the body.

28 Mar 2023

Research details how the circadian and circannual cycles influence humans at the molecular level

The daily rotation of Earth and its yearly voyage around the Sun marks the natural rhythm of life on the planet.

13 Feb 2023

Adding veliparib to chemotherapy can extend progression-free survival in patients with “BRCA-like” breast cancer

Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a "BRCA-like" phenotype.

31 Jan 2023

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Pembrolizumab has recently been approved in combination with chemotherapy for the treatment of women with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1. Chemotherapy with or without bevacizumab is possible.

25 Jan 2023

Targeting newly discovered signaling pathway could boost the potency of cancer therapeutics

Cells zealously protect the integrity of their genomes, because damage can lead to cancer or cell death. The genome -; a cell's complete set of DNA -; is most vulnerable while it is being duplicated before a cell divides. Cancer cells constantly are dividing, so their genomes are constantly in jeopardy.

24 Jan 2023

Addition of nab-paclitaxel to gemcitabine/cisplatin does not improve overall survival of patients with advanced biliary tract cancers

Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma.

20 Jan 2023

Wayne State researcher wins $1.7 million NIH award to understand and tackle cisplatin-induced ototoxicity

A Wayne State University researcher has received a $1.7 million, five-year award from the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health for the study, "Targeting nitrative stress for treatment of cisplatin ototoxicity."

5 Jan 2023

New combination of drugs may lead to improved treatment of cervical cancer

A new combination of drugs slowed the growth of cancer cells by an unexpected mechanism that may one day lead to improved treatment of cervical cancer, a UT Southwestern-led study published in Molecular Cancer Research suggests.

19 Dec 2022

Researchers develop transgenic mice with the FRET biosensor for in vivo observation of necroptosis

Necroptosis is a form of regulated cell death (RCD) similar to apoptosis, the most commonly studied type of RCD. In contrast to apoptosis, plasma membrane rupture in necroptotic cells occurs at early time points.

9 Dec 2022